Key result
Direct oral anticoagulants demonstrated superior safety compared to warfarin in patients with atrial fibrillation and cancer (p=0.04), with warfarin linked to higher mortality and hemorrhagic stroke.
Why the study?
Studies evaluating the safety of warfarin and DOACs for stroke prevention in patients with AF are lacking.
Do direct oral anticoagulants (DOACs) improve safety compared to warfarin in patients with atrial fibrillation and underlying cancer?
Cohort
Do direct oral anticoagulants (DOACs) improve safety compared to warfarin in patients with atrial fibrillation and underlying cancer?
p-value: p== 0.04
DOACs offer a safer alternative to warfarin for stroke prevention in patients with atrial fibrillation and concurrent cancer, driven by lower risks of mortality and hemorrhagic stroke.
May support DOAC preference over warfarin in AF with cancer; leaves open need for randomized confirmation.
BACKGROUND: Studies evaluating safety of warfarin and direct oral anticoagulants (DOACs) for prevention of stroke in patients with atrial fibrillation (AF) are lacking. METHODS & RESULTS: = 0.04. CONCLUSIONS: We demonstrated the superior safety profile of DOACs compared to warfarin among patients with underlying cancer and AF. Warfarin was associated with higher mortality, similar ischemic stroke risk but higher risk of hemorrhagic stroke.
No takes yet. Share an insight, caveat, or question.
Sawant et al. (2019) conducted a cohort in Atrial fibrillation and underlying cancer. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Safety profile (mortality, ischemic stroke, hemorrhagic stroke) (p== 0.04). Direct oral anticoagulants demonstrated superior safety compared to warfarin in patients with atrial fibrillation and cancer (p=0.04), with warfarin linked to higher mortality and hemorrhagic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: